1. Home
  2. MDGL vs VFS Comparison

MDGL vs VFS Comparison

Compare MDGL & VFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • VFS
  • Stock Information
  • Founded
  • MDGL 2011
  • VFS 2017
  • Country
  • MDGL United States
  • VFS Vietnam
  • Employees
  • MDGL N/A
  • VFS N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • VFS Blank Checks
  • Sector
  • MDGL Health Care
  • VFS Finance
  • Exchange
  • MDGL Nasdaq
  • VFS Nasdaq
  • Market Cap
  • MDGL 6.8B
  • VFS 6.8B
  • IPO Year
  • MDGL N/A
  • VFS N/A
  • Fundamental
  • Price
  • MDGL $290.96
  • VFS $3.60
  • Analyst Decision
  • MDGL Strong Buy
  • VFS Strong Buy
  • Analyst Count
  • MDGL 10
  • VFS 4
  • Target Price
  • MDGL $420.63
  • VFS $8.17
  • AVG Volume (30 Days)
  • MDGL 361.7K
  • VFS 468.3K
  • Earning Date
  • MDGL 05-01-2025
  • VFS 05-23-2025
  • Dividend Yield
  • MDGL N/A
  • VFS N/A
  • EPS Growth
  • MDGL N/A
  • VFS N/A
  • EPS
  • MDGL N/A
  • VFS N/A
  • Revenue
  • MDGL $317,383,000.00
  • VFS $1,727,262,130.00
  • Revenue This Year
  • MDGL $264.55
  • VFS N/A
  • Revenue Next Year
  • MDGL $67.21
  • VFS $44.69
  • P/E Ratio
  • MDGL N/A
  • VFS N/A
  • Revenue Growth
  • MDGL N/A
  • VFS 57.87
  • 52 Week Low
  • MDGL $200.08
  • VFS $2.56
  • 52 Week High
  • MDGL $377.46
  • VFS $6.42
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 40.85
  • VFS 58.39
  • Support Level
  • MDGL $280.00
  • VFS $3.52
  • Resistance Level
  • MDGL $307.54
  • VFS $3.82
  • Average True Range (ATR)
  • MDGL 15.97
  • VFS 0.13
  • MACD
  • MDGL -2.00
  • VFS 0.01
  • Stochastic Oscillator
  • MDGL 15.88
  • VFS 61.34

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About VFS VinFast Auto Ltd.

VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Automobiles, E-scooter, Spare parts & Aftermarket services. The Automobiles segment includes the design, development, manufacturing, and sales of cars and electric buses; The E-scooter segment includes the design, development, manufacturing, and sales of e-scooters; the Spare parts & Aftermarket services segment includes the sales of spare parts and rendering of aftermarket services for automobiles and e-scooters.

Share on Social Networks: